KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Emergent BioSolutions (EBS) over the last 17 years, with Q3 2025 value amounting to $1.5 billion.

  • Emergent BioSolutions' Liabilities and Shareholders Equity fell 113.68% to $1.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $5.7 billion, marking a year-over-year decrease of 1396.47%. This contributed to the annual value of $1.4 billion for FY2024, which is 2377.69% down from last year.
  • Emergent BioSolutions' Liabilities and Shareholders Equity amounted to $1.5 billion in Q3 2025, which was down 113.68% from $1.4 billion recorded in Q2 2025.
  • Over the past 5 years, Emergent BioSolutions' Liabilities and Shareholders Equity peaked at $3.2 billion during Q4 2022, and registered a low of $1.4 billion during Q4 2024.
  • For the 5-year period, Emergent BioSolutions' Liabilities and Shareholders Equity averaged around $2.2 billion, with its median value being $2.2 billion (2023).
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first soared by 2726.99% in 2021, then crashed by 4241.86% in 2023.
  • Quarter analysis of 5 years shows Emergent BioSolutions' Liabilities and Shareholders Equity stood at $3.0 billion in 2021, then rose by 7.05% to $3.2 billion in 2022, then tumbled by 42.42% to $1.8 billion in 2023, then dropped by 23.78% to $1.4 billion in 2024, then increased by 5.13% to $1.5 billion in 2025.
  • Its Liabilities and Shareholders Equity was $1.5 billion in Q3 2025, compared to $1.4 billion in Q2 2025 and $1.4 billion in Q1 2025.